Included in the formulation
АТХ:M.05.B.A.06 Ibandronic acid
Pharmacodynamics:Has an affinity for hydroxyapatite, of which the mineral skeleton of bone is composed. Due to this, it acts selectively on bone tissue, reduces its resorption, inhibits the activity of osteoclasts. Inhibits tumor osteolysis, which is manifested by a decrease in the concentration of calcium in the blood plasma and a decrease in the excretion of calcium by the kidneys. Increases bone mass, mainly in the spine.
Prevents the destruction of bone tissue, caused by blockade of the function of the gonads, tumors and retinoids. Does not directly affect the formation of bone tissue. During menopause in women reduces the increased rate of bone tissue renewal to reproductive age, resulting in decreased bone collagen degradation in blood plasma and urine, thereby reducing the incidence of fractures and increasing bone mineral density.
Pharmacokinetics:After oral ingestion, up to 0.6% is absorbed in the gastrointestinal tract.The maximum concentration in the blood plasma is reached after 2 hours. With intravenous infusion - after 30 minutes. The connection with plasma proteins is 87%. After entering the systemic bloodstream, up to 50% of ibandronic acid reaches the bone tissue and accumulates in it.
Data on the metabolism of ibandronic acid are not available.
The half-life is 10-72 hours. Elimination of the kidneys unchanged.
Indications:It is used for the treatment of postmenopausal osteoporosis, with metastatic bone damage, malignant neoplasms accompanied by hypercalcemia.
II.C76-C80.C79.5 Secondary malignant neoplasm of bone and bone marrow
II.C81-C96.C90.0 Multiple myeloma
XIII.M80-M85.M80 Osteoporosis with pathological fracture
XIII.M80-M85.M81 Osteoporosis without pathological fracture
XIII.M80-M85.M82.0 * Osteoporosis in multiple myelomatosis (C90.0 +)
XIII.M80-M85.M82 * Osteoporosis in diseases classified elsewhere
XIII.M86-M90.M89.5 Osteolysis
Contraindications:Severe renal failure, individual intolerance, children under 18 years of age.
Carefully:Renal failure of moderate severity, Paget's disease.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside once for 150 mg 60 minutes before breakfast once a month, it is recommended to stay in an upright position (not to lie down) for one hour.
The highest daily dose: 150 mg.
The highest single dose: 150 mg.
Side effects:Central nervous system: headache, asthenia, dizziness, depression, insomnia.
Digestive system: nausea, diarrhea, vomiting.
Musculoskeletal system: pain in the extremities and bones, arthralgia, myalgia, osteoarthritis, muscle stiffness, muscle spasm, in isolated cases - osteonecrosis of the jaw.
Urinary system: rarely acute renal failure after bolus injection.
Allergic reactions.
Overdose:Hypocalcemia.
Treatment is symptomatic.
Interaction:Simultaneous use of aminoglycosides increases the risk of hypocalcemia.
Drugs containing divalent cations (Ca, Fe, Mn, Mg, etc.), easily forms bonds with ibandronic acid, so these drugs can not simultaneously take inside.
Special instructions:During treatment, you need to consume enough fluids and restrict the intake of foods that contain calcium.